Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

2015 ASCO Annual Meeting /
Nivolumab extends survival for NSCLC

29th May - 2nd Jun 2015

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 29.05.15
Views: 2283
Rating:

Prof Luis Paz-Ares - Hospital Universitario 12 de Octubre, Madrid, Spain

Dr Luis Paz-Ares presents at ASCO 2015 data from a randomised phase III study that indicate PD-1 immunotherapy is an effective treatment option for patients with non-squamous, non-small cell lung cancer (NSCLC).

Read the news article and watch the interview.

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation